Eli Lilly shares phase 3 data on triple agonist weight loss drug retatrutide
Post Content
Business & Finance
Stay informed with expert takes on business strategy, investing, entrepreneurship, and global markets. CurioAtlas brings you articles that guide smarter decisions in finance and business growth.
Fed’s Mary Daly has blunt message for AI stock investors
Post Content
AI Chip Stocks Sold Off This Week. Is AMD a Buying Opportunity or a Falling Knife?
Post Content
VTI vs. VOO: Which Vanguard ETF Will Buy More SpaceX Stock After Its IPO?
Post Content
Black Rock Coffee Bar Targets 1,000 Stores as Loyalty Fuels Growth Plan
Post Content
$10,000 in Asia’s Biggest 50 Stocks Became $15,267 in Five Months: Here’s Why
Post Content
Canada PM Carney discusses trade with Indonesia’s Subianto
Post Content
Tired of nausea or taking a GLP-1 pill every day? These experimental drugs could be better than Zepbound and Wegovy.
There is a new wave of weight-loss therapies in development that aim to be better than the existing GLP-1s.
A controversial fashion giant is closing its fitting rooms
Post Content
ICLN’s 45% YTD Surge Marks a Regime Shift: From Policy Bet to Infrastructure Play, With a July Deadline Looming
Post Content